STOCK TITAN

Intellia Therape - NTLA STOCK NEWS

Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology leader pioneering CRISPR/Cas9 gene editing therapies. This page serves as the definitive source for official company announcements, including clinical trial updates, regulatory milestones, and strategic partnerships.

Investors and researchers will find curated press releases detailing NTLA's progress in treating genetic disorders like hereditary angioedema and ATTR amyloidosis. Content spans therapeutic pipeline developments, intellectual property advancements, and collaborative research initiatives with industry partners.

All materials are organized to facilitate quick scanning of critical updates while maintaining technical accuracy. Regular updates ensure stakeholders stay informed about NTLA's work in precision gene editing without promotional bias.

Bookmark this page for direct access to Intellia's latest financial reports, scientific publications, and conference participation details. Check back frequently for real-time updates on CRISPR-based therapeutic innovations.

Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) will announce its fourth quarter and full-year 2020 financial results on February 25, 2021, at 8 a.m. ET. The company focuses on developing curative therapeutics utilizing CRISPR/Cas9 technology for both in vivo and ex vivo applications. Interested participants can join the conference call by dialing the provided numbers. A replay of the call will be available later that day on the company's website. Intellia's mission is to produce permanent gene edits and engineered cells to treat various diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.18%
Tags
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) is advancing its global Phase 1 study of NTLA-2001, a single-course therapy for transthyretin amyloidosis (ATTR). The company plans to submit an IND for NTLA-5001, targeting acute myeloid leukemia (AML), by mid-2021, and another IND for NTLA-2002 for hereditary angioedema (HAE) in the second half of 2021. Intellia also aims to nominate at least one new candidate in 2021. With a strong cash position of $597 million at the end of 2020, the company is well-positioned to fund operations for the next 24 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.09%
Tags
none
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) announced progress in its gene therapy for alpha-1 antitrypsin (AAT) deficiency at the Alpha-1 Foundation’s workshop. The company demonstrated that a single course of its CRISPR/Cas9-based therapy can durably restore human AAT protein levels in non-human primates. This innovative approach could offer a potentially curative treatment for AAT deficiency, which causes liver and lung dysfunction. The stable AAT levels observed over 11 weeks indicate the treatment's promise, reinforcing Intellia's commitment to advancing its genome editing technologies for rare genetic disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Intellia Therapeutics presented promising preclinical results for NTLA-5001, a TCR-T cell therapy targeting WT1 in acute myeloid leukemia (AML), at the 62nd ASH Annual Meeting. The lead candidate demonstrated superior anti-tumor activity in mouse models compared to standard methods. The company plans to submit an IND application in H1 2021 and initiate a first-in-human trial to assess safety and efficacy in AML patients. NTLA-5001 aims at treating AML patients irrespective of genetic subtypes, with potential future applications for WT1-positive solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) announced the successful closing of a public offering of 5,513,699 shares at $36.50 per share, raising approximately $201 million before deductions. This includes the full exercise of the underwriters' option for an additional 719,178 shares. Goldman Sachs, Jefferies, and SVB Leerink were the joint book-running managers. The offering was conducted under a previously filed shelf registration statement with the SEC. The funds are expected to enhance Intellia's genome editing technology aimed at developing curative therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.25%
Tags
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) announced a public offering of 4,794,521 shares at $36.50 each, aiming to raise approximately $175 million before expenses. The underwriters, including Goldman Sachs, Jefferies, and SVB Leerink, hold a 30-day option to purchase an additional 719,178 shares. The offering is set to close around December 4, 2020. The shares are being offered under a previously filed shelf registration statement. This financing aims to support Intellia's development of CRISPR-based therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.82%
Tags
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) announced a public offering of $150 million in common stock, with an option for underwriters to purchase an additional 15% of shares. The offering is underwritten by Goldman Sachs, Jefferies, and SVB Leerink and is subject to market conditions. Shares are being sold under a previously filed shelf registration with the SEC. The company focuses on developing CRISPR/Cas9-based therapeutics. The completion of the offering depends on various factors, and the offering's size and terms may change.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ: NTLA) has received a grant from the Bill & Melinda Gates Foundation to develop non-viral treatments for sickle cell disease (SCD) using its CRISPR/Cas9 genome editing technology. This initiative aims to create safe and scalable solutions for SCD over the next 7-10 years, particularly addressing the disease's impact in developing countries. The funding will support preclinical validation of Intellia’s non-viral delivery systems for genome editing. SCD affects millions globally, with a high incidence in sub-Saharan Africa and India.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) announced the treatment of the first patient with NTLA-2001, a revolutionary potential therapy for transthyretin amyloidosis (ATTR). This groundbreaking single-course therapy utilizes CRISPR technology to potentially halt and reverse disease progression. The Phase 1 study focuses on hereditary ATTR with polyneuropathy, aiming for future trials across broader ATTR patient groups. Intellia's robust plans include rapid movement to pivotal studies, establishing NTLA-2001 as a leading candidate in curative treatments for ATTR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
Rhea-AI Summary

Intellia Therapeutics (NTLA) announced significant progress in its clinical programs, notably the initiation of a Phase 1 trial for NTLA-2001, targeting transthyretin amyloidosis (ATTR), with patient dosing expected by year-end 2020. The company also aims to submit IND applications for NTLA-5001 (acute myeloid leukemia) in 1H 2021, and NTLA-2002 (hereditary angioedema) in 2H 2021. Financially, Intellia ended Q3 2020 with $407.9 million in cash, marking a healthy increase from the previous year, despite a net loss of $27.8 million. Collaboration revenue rose significantly, driven by the Regeneron partnership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
Intellia Therape

Nasdaq:NTLA

NTLA Rankings

NTLA Stock Data

748.43M
97.95M
5.05%
91.72%
25.15%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
CAMBRIDGE